• Increase in turnover driven by activity in France and the rest of the world, experiencing growth of +40% and +73% respectively
• Third consecutive quarter of revenue growth
• Success of the proposed capital increase with preferential subscription rights for an amount of €2.77 million
Bordeaux, Boston, October 26, 2022 – 6:00 p.m. CEST: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in spinal implants, today announces its third-quarter sales 2022 and the first nine months, ended September 30, 2022.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]